...
首页> 外文期刊>Vox Sanguinis: International Journal of Blood Transfusion and Immunohaematology >In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System).
【24h】

In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System).

机译:体外评估血浆中的血液分离和悬浮的血沉棕黄层血小板成分,并用Amotosalen和UVA光化学处理过的SSP +用于病原体灭活(INTERCEPT血液系统)。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND OBJECTIVES: INTERCEPT Blood System is a pathogen inactivation system for blood components. The initial approval required a platelet component to be suspended in a combination of plasma and Platelet additive Solution/PAS-III. Improved platelet storage has been reported with Mg++ and K+ supplementation (PAS-IIIM). This study validated the use of INTERCEPT/PAS-IIIM for apheresis and pooled buffy-coat platelet components. MATERIALS AND METHODS: The platelet dose and pH throughout 5 days of storage met the European and French requirements for quality standards. RESULTS AND CONCLUSION: Additional metabolic and activation assessments of the treated platelets confirmed the previously reported superiority of PAS-IIIM over PAS-III, but extended it to the INTERCEPT process.
机译:背景与目的:截获血液系统是血液成分的病原体灭活系统。最初的批准要求将血小板成分悬浮在血浆和血小板添加剂Solution / PAS-III的组合中。据报道,补充Mg ++和K +(PAS-IIIM)可以改善血小板的储存。这项研究验证了INTERCEPT / PAS-IIIM在单采血液分离和血沉棕黄层血小板聚集成分中的应用。材料和方法:整个储存5天的血小板剂量和pH值符合欧洲和法国对质量标准的要求。结果与结论:对已治疗血小板的其他代谢和活化评估证实了先前报道的PAS-IIIM优于PAS-III,但将其扩展到了INTERCEPT过程。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号